Chondroid tenosynovial giant cell tumor of temporomandibular joint

Shetty, Sujeeth Kumar; Hegde, Usha; Agarwal, Garima; Sreeshyla, HS

doi:10.4103/ams.ams_161_18

Cited by 7 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, tumors with tyrosine kinase domains containing FGFR1 (without Ig domain) and FGFR2 were categorized as a subset of soft-tissue chondromas. However, Liu et al introduced the term CCMN to expand the classification and encompass these entities within a broader spectrum of chondroid-producing neoplasms [ 1 , 5 , 6 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intratendinous Calcified Chondroid Mesenchymal Neoplasm: A Case Report

Warburton,

Wang,

Arora

et al. 2023

jocr

View full text Add to dashboard Cite

Introduction: We present a case report concerning calcified chondroid mesenchymal neoplasms (CCMN), a novel category of tumors that exhibit chondroid formation and contain fibronectin 1-receptor tyrosine kinase fusions. Case Report: Our report focuses on a 73-year-old female patient who presented with pain in her right hip and gluteal region. Initially, the condition was misdiagnosed as calcific tendinitis based on X-ray imaging. However, a subsequent magnetic resonance imaging (MRI) revealed a solid lobulated mass originating from the right hamstring tendon origin, exhibiting heterogeneously hypointense T1-weighted signal, heterogeneously isointense proton density fat-suppressed signal, and heterogeneous contrast-enhancement compared to skeletal muscle. Further, investigation through computed tomography (CT) demonstrated intratumoral calcifications accompanied by erosive changes in the adjacent right ischial tuberosity. Histologic examination of a CT-guided biopsy confirmed the presence of large calcium pyrophosphate crystal deposits, along with benign chondroid tissue, thus supporting the diagnosis of CCMN. Notably, there is considerable overlap in the imaging characteristics of CCMN and the more commonly encountered calcific tendinitis (calcium hydroxyapatite depositional disease). Contrast-enhanced MRI findings play a crucial role in distinguishing between these two conditions. Conclusion: To the best of our knowledge, this is the first documented report describing the imaging features of CCMN across multiple modalities, including radiography, CT, and MRI. Keywords: Tumor, mass, hip.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The preferred treatment for chondroid TGCTs and soft-tissue chondromas is surgical excision [ 5 , 20 ]. This suggests that CCMN, which encompasses both entities, would also be amenable to surgical excision.…”

Section: Discussionmentioning

confidence: 99%

Intratendinous Calcified Chondroid Mesenchymal Neoplasm: A Case Report

Warburton,

Wang,

Arora

et al. 2023

jocr

View full text Add to dashboard Cite

show abstract

Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor

Monestime

Lazaridis

2020

Drugs R D

View full text Add to dashboard Cite

Tenosynovial giant cell tumor is a rare proliferative tumor that arises from the synovium, bursae, or tendon sheaths due to an overproduction of colony-stimulating factor 1. Historically, treatment options for patients with local or diffuse tenosynovial giant cell tumor have been limited to surgical interventions. However, for some patients, surgical resection could worsen functional limitations and/or morbidity. In August 2019, the FDA approved pexidartinib (TURALIO™, Daiichi Sankyo), the first systemic treatment option for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations that were not amenable to improvement with surgery. Pexidartinib is an oral tyrosine kinase inhibitor with selective inhibition of colony-stimulating factor 1 receptor and is the first systemic therapy to show significant improvement in overall response rates when compared with placebo. Clinicians using pexidartinib should monitor for liver-related adverse events, which may require treatment interruption, dose reduction, or treatment discontinuation. Pexidartinib provides a novel non-surgical treatment option for patients with tenosynovial giant cell tumor that may significantly improve patients’ overall response, range of motion, physical function, tumor volume, and stiffness.

show abstract